Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Affimed NV Market Cap
Based on ratings from 7 stock analysts, the Affimed NV stock price is expected to increase by 729.83% in 12 months. This is calculated by using the average 12-month stock price forecast for Affimed NV. The lowest target is $5.48778 and the highest is $65.78745. Please note analyst price targets are not guaranteed and could be missed completely.
AFMD is a stock in Healthcare which has been forecasted to be worth $26.63766 as an average. On the higher end, the forecast price is $65.78745 USD by from and on the lower end AFMD is forecasted to be $5.48778 by from .
These are the latest 20 analyst ratings of AFMD.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Li Watsek Cantor Fitzgerald | Overweight | Reiterates | Sep 9, 2024 | |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $10 | Reiterates | Sep 6, 2024 |
| Yale Jen Laidlaw & Co. | Buy | $25 | Maintains | Jun 13, 2024 |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $10 | Reiterates | Jun 13, 2024 |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $10 | Reiterates | Jun 3, 2024 |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $10 | Maintains | Apr 1, 2024 |
| Li Watsek Cantor Fitzgerald | Overweight | Reiterates | Apr 1, 2024 | |
| Bradley Canino Stifel | Hold | $5 | Maintains | Apr 1, 2024 |
| Yanan Zhu Wells Fargo | Overweight | $25 | Maintains | Apr 1, 2024 |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $5 | Reiterates | Nov 15, 2023 |
| Li Watsek Cantor Fitzgerald | Overweight | $7 | Reiterates | Sep 25, 2023 |
| Li Watsek Cantor Fitzgerald | Overweight | $7 | Reiterates | Sep 12, 2023 |
| Li Watsek Cantor Fitzgerald | Overweight | $7 | Reiterates | Sep 7, 2023 |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $5 | Reiterates | Aug 11, 2023 |
| Srikripa Devarakonda Truist Securities | Buy | $6 | Maintains | Aug 11, 2023 |
| Andy Chen Berenberg | Buy | $6 | Assumes | Aug 8, 2023 |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $5 | Maintains | Jun 5, 2023 |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $6 | Reiterates | May 24, 2023 |
| Yanan Zhu Wells Fargo | Overweight | $7 | Assumes | Mar 27, 2023 |
| Bradley Canino Stifel | Hold | $1 | Maintains | Mar 24, 2023 |
When did it IPO
2014
Staff Count
76
Country
Germany
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Andreas Harstrick M.D.
Market Cap
$50.6M
In 2023, AFMD generated $8.3M in revenue, which was a decrease of -79.99% from the previous year. This can be seen as a signal that AFMD's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 10 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Affimed N.V. CEO Shawn M. Leland will speak at the Cantor Global Healthcare Conference on September 17, 2024, at 8:00 a.m. EDT.
Why It Matters - CEO participation in a major healthcare conference can signal company progress and attract investor interest, potentially impacting stock performance and market perception.
Thu, 05 Sep 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Affimed N.V. (NASDAQ:AFMD) will hold its Q2 2024 earnings conference call on September 5, 2024, at 8:30 AM ET, featuring key company executives and analysts from various firms.
Why It Matters - The earnings call reveals key insights into Affimed's financial health and strategic direction, influencing market sentiment and investment decisions in the biotech sector.
Thu, 05 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Affimed N.V. reported its Q2 2024 financial results and updates on clinical and corporate progress, emphasizing its focus on immuno-oncology therapies for cancer treatment.
Why It Matters - Affimed's financial results and clinical updates indicate its progress in the competitive immuno-oncology sector, impacting investor sentiment and potential stock performance.
Wed, 04 Sep 2024
Sentiment - NEUTRAL
Source - Zacks Investment Research
Summary - AFMD has appointed Shawn M. Leland as the new CEO.
Why It Matters - Leadership changes can impact company strategy and performance. Investors will assess Leland's track record and vision to gauge future growth potential and stock performance.
Wed, 04 Sep 2024
Sentiment - POSITIVE
Source - Seeking Alpha
Summary - Affimed's stock rose after a positive acimtamig update but has since fallen below $4, likely due to concerns over a potential dilutive capital raise. Earnings Call on 09/05/24; updates expected by month-end.
Why It Matters - Affimed's stock is under pressure due to concerns over a potential dilutive capital raise, impacting investor sentiment ahead of key earnings and product updates.
Tue, 03 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Affimed N.V. appointed Shawn M. Leland as CEO, effective immediately, while Dr. Andreas Harstrick remains as Chief Medical Officer.
Why It Matters - The appointment of a new CEO can signal a shift in strategy and leadership vision, impacting investor confidence and potentially affecting stock performance for Affimed N.V.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
